HuGE Literature Finder
Records
1
-
4
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 2014 Aug 5 (15): 6280-8. Lambert Juliette, Lambert Jérôme, Nibourel Olivier, Pautas Cécile, Hayette Sandrine, Cayuela Jean-Michel, Terré Christine, Rousselot Philippe, Dombret Hervé, Chevret Sylvie, Preudhomme Claude, Castaigne Sylvie, Renneville Ali |
The prognostic value of CXCR4 in acute myeloid leukemia. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2013 Jan 21 (1): 79-84. Ahn Jeong Yeal, Seo Katie, Weinberg Olga K, Arber Daniel |
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009 May 113 (21): 5250-3. Schneider Friederike, Hoster Eva, Unterhalt Michael, Schneider Stephanie, Dufour Annika, Benthaus Tobias, Mellert Gudrun, Zellmeier Evelin, Bohlander Stefan K, Feuring-Buske Michaela, Buske Christian, Braess Jan, Fritsch Susanne, Heinecke Achim, Sauerland Maria C, Berdel Wolfgang E, Buechner Thomas, Woermann Bernhard J, Hiddemann Wolfgang, Spiekermann Karst |
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009 Jan 94 (1): 54-60. Schlenk Richard F, Döhner Konstanze, Kneba Michael, Götze Katharina, Hartmann Frank, Del Valle Francesco, Kirchen Heinz, Koller Elisabeth, Fischer Jörg T, Bullinger Lars, Habdank Marianne, Späth Daniela, Groner Silja, Krebs Bernhard, Kayser Sabine, Corbacioglu Andrea, Anhalt Andreas, Benner Axel, Fröhling Stefan, Döhner Hartmut, |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: